Dimethylglycine
|
Basic information |
| Metabolite name | Dimethylglycine |
 | HMDB0000092 |
 |
C01026 |
 |
673 |
| Synonyms | N,N-dimethylglycine |
| No. of studies | 22 |
|
Basic information |
| Metabolite name | Dimethylglycine |
| HMDB0000092 |
|
C01026 |
|
673 |
| Synonyms | N,N-dimethylglycine |
| No. of studies | 22 |
|
Relationship between Dimethylglycine and depression (count: 22) |
| Study | Study Type  |
Comparison groups | Tissue | Organism | Up/Down regulated |
| Study M006 | Type1 | depressed group vs. control group | Plasma | Human | Down |
| Study M016 | Type1 | CUMS group vs. control group | Urine | Sprague-Dawley rat | Down |
| Study M036 | Type1 | MDD group vs. control group | Urine | Human | Down |
| Study M043 | Type1 | chronic hepatitis B patients with MDD group vs. without MDD group | Urine | Human | Up |
| Study M058 | Type1 | depressed HBV-infected patients group vs. control group and non-depressed HBV-infected group | Urine | Human | Up |
| Study M077 | Type1 | non-weaned group vs. weaned group | Urine | Wistar rat | Down |
| Study M077 | Type1 | non-weaned FST group vs. weaned FST group | Urine | Wistar rat | Down |
| Study M1041 | Type2 | pilocarpine + mitochondrial transplantation group vs. pilocarpine group | Hippocampus | C57BL/6J mouse | Down |
| Study M1056 | Type1 | maternal separation group vs. control group | Serum | Sprague-Dawley rat | Up |
| Study M1102 | Type1 | nitenpyram group vs. control group, male offspring | Faece | ICR mouse | Down |
| Study M116 | Type3 | ketamine group vs. control group | Cerebrospinal fluid | Sprague-Dawley rat | Down |
| Study M472 | Type3 | (2R,6R)-HNK group vs. control group | PC12 cell | Rat | Up |
| Study M472 | Type3 | (2S,6S)-HNK group vs. control group | PC12 cell | Rat | Down |
| Study M567 | Type1 | FSL group vs. FRL group | Plasma | Sprague-Dawley rat | Up |
| Study M631 | Type1 | CUMS group vs. control group | Serum | Kunming mouse | Down |
| Study M631 | Type2 | CUMS + high dose of iridoid-rich fraction of V. jatamansi group vs. CUMS group | Serum | Kunming mouse | Up |
| Study M686 | Type1 | depression group vs. control group | Urine | Human | Up |
| Study M712 | Type1 | depression group vs. control group | Hippocampus | Cynomolgus monkey | Down |
| Study M748 | Type1 | short-day group vs. long-day group | Plasma | C57BL/6 J mouse | Down |
| Study M823 | Type2 | CUMS + albiflorin group vs. CUMS group | Hippocampus | Sprague-Dawley rat | Up |
| Study M839 | Type1 | MDD group vs. control group | Plasma | Human | Down |
| Study M840 | Type1 | casein-rich milk group vs. control group | Urine | Wistar rat | Down |
| Study M905 | Type1 | subclinical depression group vs. control group | Urine | Human | Up |
| Study M913 | Type2 | responder group, post-escitalopram treatment vs. baseline | Plasma | Human | Up |
| Study M975 | Type1 | CUMS group vs. control group | Urine | Sprague-Dawley rat | Down |
| Study M975 | Type2 | CUMS + high dose of Yang-Xin-Jie-Yu Decoction group vs. CUMS group | Urine | Sprague-Dawley rat | Down |
| Study M975 | Type2 | CUMS + middle dose of Yang-Xin-Jie-Yu Decoction group vs. CUMS group | Urine | Sprague-Dawley rat | Down |
| Study M975 | Type2 | CUMS + low dose of Yang-Xin-Jie-Yu Decoction group vs. CUMS group | Urine | Sprague-Dawley rat | Down |
| Study M975 | Type2 | CUMS + fluoxetine group vs. CUMS group | Urine | Sprague-Dawley rat | Up |